CN100381160C - Chinese medicine for treating B-type hepatitis - Google Patents

Chinese medicine for treating B-type hepatitis Download PDF

Info

Publication number
CN100381160C
CN100381160C CNB2005101230410A CN200510123041A CN100381160C CN 100381160 C CN100381160 C CN 100381160C CN B2005101230410 A CNB2005101230410 A CN B2005101230410A CN 200510123041 A CN200510123041 A CN 200510123041A CN 100381160 C CN100381160 C CN 100381160C
Authority
CN
China
Prior art keywords
radix
chinese medicine
root
traditional chinese
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005101230410A
Other languages
Chinese (zh)
Other versions
CN1814254A (en
Inventor
陈计强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2005101230410A priority Critical patent/CN100381160C/en
Publication of CN1814254A publication Critical patent/CN1814254A/en
Application granted granted Critical
Publication of CN100381160C publication Critical patent/CN100381160C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The present invention discloses a traditional Chinese medicine for treating hepatitis B. The traditional Chinese medicine is prepared from raw material medicines of parasite scurrula, morinda root, radix polygoni multiflori, liao Chinese magnolivine fruit, stir-fried big head atractylodes rhizome, prepared licorice root, dried orange peel, red sage root, ground beetle, lithospermum, gamene, jiafengfang, bee dead body, paris root, dried gecko, niujiaosi, stringy stonecrop, curcuma root, China root, lightyellow sophora root and giant knotweed rhizome according to a proportion. The traditional Chinese medicine can be prepared into any oral administration dosage form according to a conventional method of traditional Chinese medicine preparation. The traditional Chinese medicine of the present invention has the advantages of the treatment of hepatic disease at an early stage and high curative rate.

Description

The Chinese medicine of treatment hepatitis B disease
Technical field
The invention belongs to the field of Chinese medicines, particularly a kind of early treatment's medicine that is applicable to hepatitis B diseases.
Background technology
The hepatitis B disease is one of at present common clinically pertinacious disease.Particularly the HBV-DNA positive patient of early stage light symptoms is not more paid attention to by people, and who does not know that HBV-DNA virus is constantly duplicated in human body, until developing into chronic hepatitis, liver cirrhosis, canceration of hepatic cell etc.How inhibition of hepatitis b virus duplicates in that the people is intravital, removes HBV-DNA virus and has the important clinical meaning.Hepatitis B virus is invaded the human body principal element, and the heresy of positive QI-insufficiency, epidemic disease poison is taken advantage of a weak point.Liver,spleen,kidney three dirty functional disorders.Adhere to taking medicine if can correctly treat in early days, most of patient can cure.
Summary of the invention
The objective of the invention is pathogeny, a kind of Chinese patent medicine that is applicable to the sick early treatment of hepatitis B is provided according to the hepatitis B disease.
The technical solution adopted in the present invention is as follows: a kind of Chinese medicine for the treatment of the hepatitis B disease is characterized in that being made by the crude drug of following weight:
Radix Astragali 1-10 part Radix Angelicae Sinensis 1-5 part Ganoderma lucidum seu Japonicum 1-9 part
Formica fusca 1-10 part Herba Taxilli 1-6 part FRUCTUS SCHISANDRAE from Liaoning of China 1-8 part
Radix Morindae Officinalis 1-7 part Radix Polygoni Multiflori 1-5 part Rhizoma Atractylodis Macrocephalae (parched) 1-5 part
Radix Glycyrrhizae Preparata 1-5 part Pericarpium Citri Reticulatae 1-5 part Radix Salviae Miltiorrhizae 1-5 part
Eupolyphaga 0.5-3 part Radix Arnebiae (Radix Lithospermi) 1-8 part Radix Rubiae 1-8 part
The Nidus Vespae 1-9 of family part bee corpse 1-20 part Rhizoma Paridis 1-5 part
Gekko Swinhonis 0.5-2 part Cornu Bovis seu Bubali silk 1-8 part Herba Sedi 1-9 part
Rhizoma Polygoni Cuspidati 1-8 part Radix Curcumae 1-6 part Rhizoma Smilacis Glabrae 1-10
Radix Sophorae Flavescentis 1-6 part
Drug component of the present invention and consumption are that the inventor gropes to sum up to draw in a large number, all have better curative effect in above-mentioned weight portion scope.
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations.For example can be with these crude drug decocting together, the condensed water decocting liquid is made oral decoction then.Also can extract its active ingredient and make pill, powder etc. again with ethanol extraction method.Incapsulate after also these crude drug pulverizes can being combined evenly, frying and make capsule.
The mechanism of curing the disease of the present invention is: the traditional Chinese medical science is in a new stage hepatitis B virus understanding, modern Chinese medicine has been inherited the theory of Chinese medicine, and broken away from the constraint of Chinese medicine, quoted advanced Western medicine diagnose technology, with traditional theory of Chinese medical science and the organic combination of present-day medical knowledge.Thereby as adopt fluorescent technique to look into the quantitative basis that HBV-DNA has quantitatively formed tcm diagnosis and treatment hepatopathy science." Ling Shu Miraculous Pivot or Divine Axis, all kinds of diseases and ailments beginning gives birth to the 66 " points out, wind and rain cold and heat, must not be empty, heresy can not solely be hurted sb.'s feelings, this must be because of the wind of exogenous pathogen, with its body, interaction between two asthenia conditions, be its shape of visitor " illustrate that healthy energy deposits interior, heresy and can not do.Reuse the Radix Astragali, Radix Angelicae Sinensis, Ganoderma lucidum seu Japonicum, Formica fusca qi-supplementing, blood-engendering, mediator's body immunity function in the side.Blood stored in the liver, main catharsis The spleen governs the blood master fortune, kidney storing essence, main water again.So irritability bar Danone evacuate temper stop up fortuneization strongly fragrant, spleen can prevent kidney water close open not normal.Herba Taxilli, Radix Morindae Officinalis, Radix Polygoni Multiflori, FRUCTUS SCHISANDRAE from Liaoning of China, the liver and the kidney tonifying.Rhizoma Atractylodis Macrocephalae (parched), Radix Glycyrrhizae Preparata, Pericarpium Citri Reticulatae the spleen strengthening and damp drying are to help temper.Rhizoma Polygoni Cuspidati, Radix Salviae Miltiorrhizae, eupolyphaga, activating blood circulation to dissipate blood stasis are regulated microcirculation.The heresy of so-called epidemic disease poison, Liu's interchannel call eqpidemic disease " infection " in " principal and secondary syndromes of exogenous febrile disease ".Sky again can be in " pestilence opinion " further proposes " institute of heresy, have day be subjected to, have infection ", and these record and narrate heresies genus pestilence category of explanation epidemic disease poison, should be the rule of treatment with the heat-clearing and toxic substances removing.Radix Arnebiae (Radix Lithospermi), Radix Rubiae, Radix Et Rhizoma Rhei, bee corpse, Rhizoma Paridis, tame Nidus Vespae, Gekko Swinhonis, Cornu Bovis seu Bubali silk, Herba Sedi, Radix Curcumae, Rhizoma Smilacis Glabrae, Radix Sophorae Flavescentis have heat-clearing and toxic substances removing and remove the epidemic disease toxic action.Above-mentioned by the medicine use in conjunction, play strengthening vital QI to eliminate pathogenic factors, heat-clearing and toxic substances removing altogether except that the epidemic disease effect.Through clinical verification HBV-DVA virus is really blocked the effect of duplicating preferably.Adhere to medication, can suppress of the harm of HBV-DVA virus human body.
The utility model has the advantages that: can be used for hepatitis B virus carriers, implement the early treatment of hepatopathy.
The specific embodiment
Further set forth the effect of medicine of the present invention by the following examples with clinical observation on the therapeutic effect.
The capsule preparation of embodiment 1 medicine of the present invention
With 8 parts of the Radixs Astragali, 3 parts of Radix Angelicae Sinensis, 5 parts of Ganoderma lucidum seu Japonicumes, 6 parts of Formica fuscas, 2 parts of Herba Taxillis, 6 parts of FRUCTUS SCHISANDRAE from Liaoning of China, 5 parts of Radix Morindae Officinaliss, 2 parts of Radix Polygoni Multiflori, 2 parts of Rhizoma Atractylodis Macrocephalae (parched)s, 2 parts in Radix Glycyrrhizae, 2 parts of Pericarpium Citri Reticulataes, 2 parts of Radix Salviae Miltiorrhizaes, 1 part of eupolyphaga, 5 parts of Radix Arnebiae (Radix Lithospermi)s, 5 parts in Radix Rubiae, 7 parts in tame Nidus Vespae, 15 parts of bee corpses, 4 parts of Rhizoma Paridiss, 2 parts of Gekko Swinhonis, 2 parts of Cornu Bovis seu Bubali silk, 6 parts of Herba Sedis, 5 parts of Rhizoma Polygoni Cuspidati, 4 parts of Radix Curcumaes, 8 parts of Rhizoma Smilacis Glabraes and 4 parts of mix homogeneously of Radix Sophorae Flavescentis; Grind into powder is crossed 200 mesh sieves then; Fry the capsule of packing into after the cooling No. 0 then.Every content 0.5g.
The test example, the clinical observation of Drug therapy hepatitis B disease of the present invention
1, physical data:
Select 60 examples that the treatment of light symptoms HBV-DNA positive patient is arranged in early days, all to go to the hospital HBV-DNA is done quantitative check through secondary.Quantitatively all positive (quantitative fluorescent PCR) method of HBV-DNA as a result.Male 38 examples in the base, women's 22 examples, the oldest 35 years old, minimum 15 years old, 25.1 years old mean age, 15 to 25 years old 40 example, 26 to 35 years old 20 example, the course of disease is Check-Out Time, does not wait to 1 year in 1 month.
2, Therapeutic Method:
With embodiment 1 gained medicine, every content 0.5g, every day 3 times, takes after meal half an hour by each 12.Three months is a course of treatment.Period in a medicine ban on opium-smoking and the opium trade, sexual life, fatigue.
3, observation of curative effect
Produce effects: obey according to quantity and look into HBV-DNA quantitative target decline three/the two 56 example a course of treatment.
Clinical cure; Look into HBV-DNA quantitatively less than 1.0 * 10 three to five courses of treatment 3Person's 32 examples.
Invalid: as to look into quantitative no change person 4 examples of HBV-DNA a course of treatment.
Allusion quotation shape case
The Wang, man 21 years old did manual work in foreign enterprise and to find great three positive in 2002.HBV-DNA quantitatively is 5.39 * 10 8, liver function is normal, clothes hepatitis B virus capsule, and each 6 grams three times on the one are obeyed after meal half an hour, serve on four courses of treatment and look into HBV-DNA quantitatively less than 1.0 * 10 3, two and half feminine genders.
Ma, the man, 28 years old, peasant HBV-DNA quantitative 3.5 * 10 7
Normal, the two and half demonstration great three positives of liver function.One time 6 gram of clothes hepatitis B virus clearing capsule, three times on the one, to obey half an hour after meal, look into HBV-DNA quantitatively less than 10 * 10 two courses of treatment 3And two half show the HBSAg positive, the anti-HBC positive.

Claims (1)

1. Chinese medicine for the treatment of the hepatitis B disease is characterized in that being made by the crude drug of following weight:
Radix Astragali 1-10 part Radix Angelicae Sinensis 1-5 part Ganoderma lucidum seu Japonicum 1-9 part
Formica fusca 1-10 part Herba Taxilli 1-6 part FRUCTUS SCHISANDRAE from Liaoning of China 1-8 part
Radix Morindae Officinalis 1-7 part Radix Polygoni Multiflori 1-5 part Rhizoma Atractylodis Macrocephalae (parched) 1-5 part
Radix Glycyrrhizae 1-5 part Pericarpium Citri Reticulatae 1-5 part Radix Salviae Miltiorrhizae 1-5 part
Eupolyphaga 0.5-3 part Radix Arnebiae (Radix Lithospermi) 1-8 part Radix Rubiae 1-8 part
The Nidus Vespae 1-9 of family part bee corpse 1-20 part Rhizoma Paridis 1-5 part
Gekko Swinhonis 0.5-2 part Cornu Bovis seu Bubali silk 1-8 part Herba Sedi 1-9 part
Rhizoma Polygoni Cuspidati 1-8 part Radix Curcumae 1-6 part Rhizoma Smilacis Glabrae 1-10
Radix Sophorae Flavescentis 1-6 part.
CNB2005101230410A 2005-12-07 2005-12-07 Chinese medicine for treating B-type hepatitis Expired - Fee Related CN100381160C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005101230410A CN100381160C (en) 2005-12-07 2005-12-07 Chinese medicine for treating B-type hepatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005101230410A CN100381160C (en) 2005-12-07 2005-12-07 Chinese medicine for treating B-type hepatitis

Publications (2)

Publication Number Publication Date
CN1814254A CN1814254A (en) 2006-08-09
CN100381160C true CN100381160C (en) 2008-04-16

Family

ID=36906685

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005101230410A Expired - Fee Related CN100381160C (en) 2005-12-07 2005-12-07 Chinese medicine for treating B-type hepatitis

Country Status (1)

Country Link
CN (1) CN100381160C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101869603B (en) * 2009-04-24 2012-03-14 上海中医药大学附属曙光医院 Traditional Chinese medicine composite for protecting livers and preventing liver injury and preparation method thereof
CN101890097B (en) * 2009-05-18 2014-11-26 肖风刚 Chinese medicinal composite biopolypeptide composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1175459A (en) * 1997-09-18 1998-03-11 李良云 Specific infusion for hepatitis B and producing process thereof
CN1183978A (en) * 1997-10-29 1998-06-10 鄂州市梁子湖区公友卫生院 Hepatitis B curing honeyed ointment and its preperation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1175459A (en) * 1997-09-18 1998-03-11 李良云 Specific infusion for hepatitis B and producing process thereof
CN1183978A (en) * 1997-10-29 1998-06-10 鄂州市梁子湖区公友卫生院 Hepatitis B curing honeyed ointment and its preperation

Also Published As

Publication number Publication date
CN1814254A (en) 2006-08-09

Similar Documents

Publication Publication Date Title
CN102755594B (en) Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof
CN100441212C (en) Chinese medicine for treating cardiac failure
CN101380417A (en) Preparation for quickly treating urticaria
CN103860699B (en) A kind of pharmaceutical composition for effecting a radical cure three-hypers
CN108478731A (en) Chinese medicine preparation and Chinese medicinal capsule for treating cardiovascular stasis coronary heart disease
CN1150928C (en) Medicine for curing cancers and its preparation method
CN103356968B (en) Traditional Chinese medicine composition for treating endometriosis
CN102526677A (en) Chinese medicine foot-massage composition for treating common cold due to wind-cold
CN100381160C (en) Chinese medicine for treating B-type hepatitis
CN101167932A (en) Traditional Chinese medicine for treating chronic hepatitis B
CN101361949A (en) Traditional Chinese medicine for treating gynaecologic emmeniopathy
CN108014303A (en) A kind of Chinese medicine preparation for treating Ru Repair-in and preparation method thereof
CN104189847A (en) Traditional Chinese medicine for treating tuberculous exadative pleurisy
CN104189473A (en) Pharmaceutical composition for treating tuberculosis and preparation method thereof
CN103479835A (en) Traditional Chinese medicine for treating liver cirrhosis
CN101085088A (en) Traditional Chinese medicine formula for treating prostatic hyperplasia
CN102488751A (en) Chinese medicinal preparation for treating infantile diarrhea
CN102114211B (en) Chinese herbal medicine for treating hepatopathy
CN101953925A (en) Traditional Chinese medicine for treating chronic hepatitis
CN104162043A (en) Traditional Chinese medicine used for treatment of allergic nodular cutaneous vasculitis
CN103566219A (en) Traditional Chinese medicine composition for treating cold
CN101773643B (en) Chinese medicine preparation for treating mammary gland proliferation diseases and preparation method thereof
Lee et al. Case Report of a Psychogenic Urinary Incontinence Patient with Hypersomnia Disorder
CN101745074A (en) Chinese medicinal herb for enhancing immunity
CN100998720B (en) Oral traditional Chinese medicine for treating amenorrhea of uterus stasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080416

Termination date: 20100107